IFNG and relapsing-remitting multiple sclerosis: RRMS patients treated with IFN-β were found to have increased levels of neuroprotective KYN compared with untreated RRMS patients (77), whereas glucocorticoid treatment significantly reduced IFN-γ levels and IDO-1 expression.